Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane
Paclitaxel poliglumex (CT-2103; XYOTAX) is an innovative macromolecular taxane designed to increase the therapeutic index of paclitaxel. This large macromolecule conjugate of paclitaxel and poly-L-glutamic acid accumulates in tumor tissues by taking advantage of the enhanced permeability of tumor va...
Gespeichert in:
| Veröffentlicht in: | Anti-cancer drugs 2005-03, Vol.16 (3), p.243-254 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 254 |
|---|---|
| container_issue | 3 |
| container_start_page | 243 |
| container_title | Anti-cancer drugs |
| container_volume | 16 |
| creator | Singer, Jack W Shaffer, Scott Baker, Brian Bernareggi, Alberto Stromatt, Scott Nienstedt, Drew Besman, Marc |
| description | Paclitaxel poliglumex (CT-2103; XYOTAX) is an innovative macromolecular taxane designed to increase the therapeutic index of paclitaxel. This large macromolecule conjugate of paclitaxel and poly-L-glutamic acid accumulates in tumor tissues by taking advantage of the enhanced permeability of tumor vasculature and lack of lymphatic drainage. Paclitaxel poliglumex prolongs exposure to active drug and minimizes systemic exposure. Preclinical studies in animal tumor models demonstrate enhanced safety and efficacy relative to paclitaxel when administered as a single agent or in conjunction with radiation. Clinical pilot studies with paclitaxel poliglumex showed improved outcomes compared to standard taxanes and allowed a more convenient administration schedule. Human pharmacokinetic data are consistent with prolonged tumor exposure to active drug and a limited systemic exposure. Based on these results, three ongoing randomized phase III trials were initiated to test the efficacy of paclitaxel poliglumex in patients with advanced non-small cell lung carcinoma. |
| doi_str_mv | 10.1097/00001813-200503000-00003 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_wolte</sourceid><recordid>TN_cdi_pubmed_primary_15711176</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15711176</sourcerecordid><originalsourceid>FETCH-LOGICAL-p1843-1d19757cf7d62935565235206ad625084080e2c90da077c61b40aa7a2f5833e63</originalsourceid><addsrcrecordid>eNp1kM1PwkAQxTdGI4j-C6ZHPazOdHa7XT2Rxq9IggdM8NQM7QLVBZp-BPjvrUGPzmXmvfzykjdCBAg3CNbcQjcYI8kQQAN1Sv5YdCT6qAxJbRQeiz5YbaWyhnrirK4_O6Lz6VT0UBtENFFfvL5x5ouGd84H5cYXC9-u3C64mn6MJ8PpfZBMZIhA13cBr4Ni3VScOe9bz5XfBw1XC9e4vDt2vHbn4mTOvnYXv3sg3h8fJsmzHI2fXpLhSJYYK5KYozXaZHOTR6ElrSMdkg4h4k5riBXE4MLMQs5gTBbhTAGz4XCuYyIX0UBcHnLLdrZyeVpWxYqrffrXqgPUAdhufOOq-su3W1elS8e-Wab_PY--AXHDXJU</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Singer, Jack W ; Shaffer, Scott ; Baker, Brian ; Bernareggi, Alberto ; Stromatt, Scott ; Nienstedt, Drew ; Besman, Marc</creator><creatorcontrib>Singer, Jack W ; Shaffer, Scott ; Baker, Brian ; Bernareggi, Alberto ; Stromatt, Scott ; Nienstedt, Drew ; Besman, Marc</creatorcontrib><description>Paclitaxel poliglumex (CT-2103; XYOTAX) is an innovative macromolecular taxane designed to increase the therapeutic index of paclitaxel. This large macromolecule conjugate of paclitaxel and poly-L-glutamic acid accumulates in tumor tissues by taking advantage of the enhanced permeability of tumor vasculature and lack of lymphatic drainage. Paclitaxel poliglumex prolongs exposure to active drug and minimizes systemic exposure. Preclinical studies in animal tumor models demonstrate enhanced safety and efficacy relative to paclitaxel when administered as a single agent or in conjunction with radiation. Clinical pilot studies with paclitaxel poliglumex showed improved outcomes compared to standard taxanes and allowed a more convenient administration schedule. Human pharmacokinetic data are consistent with prolonged tumor exposure to active drug and a limited systemic exposure. Based on these results, three ongoing randomized phase III trials were initiated to test the efficacy of paclitaxel poliglumex in patients with advanced non-small cell lung carcinoma.</description><identifier>ISSN: 0959-4973</identifier><identifier>EISSN: 1473-5741</identifier><identifier>DOI: 10.1097/00001813-200503000-00003</identifier><identifier>PMID: 15711176</identifier><language>eng</language><publisher>England: Lippincott Williams & Wilkins, Inc</publisher><subject>Animals ; Antineoplastic Agents - therapeutic use ; Area Under Curve ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Drug Synergism ; Female ; Half-Life ; Humans ; Lung Neoplasms - drug therapy ; Mice ; Ovarian Neoplasms - drug therapy ; Paclitaxel - therapeutic use ; Polyglutamic Acid - metabolism ; Polyglutamic Acid - pharmacokinetics ; Polyglutamic Acid - therapeutic use ; Randomized Controlled Trials as Topic ; Taxoids - metabolism ; Taxoids - pharmacokinetics ; Taxoids - therapeutic use</subject><ispartof>Anti-cancer drugs, 2005-03, Vol.16 (3), p.243-254</ispartof><rights>2005 Lippincott Williams & Wilkins, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15711176$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Singer, Jack W</creatorcontrib><creatorcontrib>Shaffer, Scott</creatorcontrib><creatorcontrib>Baker, Brian</creatorcontrib><creatorcontrib>Bernareggi, Alberto</creatorcontrib><creatorcontrib>Stromatt, Scott</creatorcontrib><creatorcontrib>Nienstedt, Drew</creatorcontrib><creatorcontrib>Besman, Marc</creatorcontrib><title>Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane</title><title>Anti-cancer drugs</title><addtitle>Anticancer Drugs</addtitle><description>Paclitaxel poliglumex (CT-2103; XYOTAX) is an innovative macromolecular taxane designed to increase the therapeutic index of paclitaxel. This large macromolecule conjugate of paclitaxel and poly-L-glutamic acid accumulates in tumor tissues by taking advantage of the enhanced permeability of tumor vasculature and lack of lymphatic drainage. Paclitaxel poliglumex prolongs exposure to active drug and minimizes systemic exposure. Preclinical studies in animal tumor models demonstrate enhanced safety and efficacy relative to paclitaxel when administered as a single agent or in conjunction with radiation. Clinical pilot studies with paclitaxel poliglumex showed improved outcomes compared to standard taxanes and allowed a more convenient administration schedule. Human pharmacokinetic data are consistent with prolonged tumor exposure to active drug and a limited systemic exposure. Based on these results, three ongoing randomized phase III trials were initiated to test the efficacy of paclitaxel poliglumex in patients with advanced non-small cell lung carcinoma.</description><subject>Animals</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Area Under Curve</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Drug Synergism</subject><subject>Female</subject><subject>Half-Life</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Mice</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Paclitaxel - therapeutic use</subject><subject>Polyglutamic Acid - metabolism</subject><subject>Polyglutamic Acid - pharmacokinetics</subject><subject>Polyglutamic Acid - therapeutic use</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Taxoids - metabolism</subject><subject>Taxoids - pharmacokinetics</subject><subject>Taxoids - therapeutic use</subject><issn>0959-4973</issn><issn>1473-5741</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM1PwkAQxTdGI4j-C6ZHPazOdHa7XT2Rxq9IggdM8NQM7QLVBZp-BPjvrUGPzmXmvfzykjdCBAg3CNbcQjcYI8kQQAN1Sv5YdCT6qAxJbRQeiz5YbaWyhnrirK4_O6Lz6VT0UBtENFFfvL5x5ouGd84H5cYXC9-u3C64mn6MJ8PpfZBMZIhA13cBr4Ni3VScOe9bz5XfBw1XC9e4vDt2vHbn4mTOvnYXv3sg3h8fJsmzHI2fXpLhSJYYK5KYozXaZHOTR6ElrSMdkg4h4k5riBXE4MLMQs5gTBbhTAGz4XCuYyIX0UBcHnLLdrZyeVpWxYqrffrXqgPUAdhufOOq-su3W1elS8e-Wab_PY--AXHDXJU</recordid><startdate>200503</startdate><enddate>200503</enddate><creator>Singer, Jack W</creator><creator>Shaffer, Scott</creator><creator>Baker, Brian</creator><creator>Bernareggi, Alberto</creator><creator>Stromatt, Scott</creator><creator>Nienstedt, Drew</creator><creator>Besman, Marc</creator><general>Lippincott Williams & Wilkins, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>200503</creationdate><title>Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane</title><author>Singer, Jack W ; Shaffer, Scott ; Baker, Brian ; Bernareggi, Alberto ; Stromatt, Scott ; Nienstedt, Drew ; Besman, Marc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p1843-1d19757cf7d62935565235206ad625084080e2c90da077c61b40aa7a2f5833e63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Area Under Curve</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Drug Synergism</topic><topic>Female</topic><topic>Half-Life</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Mice</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Paclitaxel - therapeutic use</topic><topic>Polyglutamic Acid - metabolism</topic><topic>Polyglutamic Acid - pharmacokinetics</topic><topic>Polyglutamic Acid - therapeutic use</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Taxoids - metabolism</topic><topic>Taxoids - pharmacokinetics</topic><topic>Taxoids - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Singer, Jack W</creatorcontrib><creatorcontrib>Shaffer, Scott</creatorcontrib><creatorcontrib>Baker, Brian</creatorcontrib><creatorcontrib>Bernareggi, Alberto</creatorcontrib><creatorcontrib>Stromatt, Scott</creatorcontrib><creatorcontrib>Nienstedt, Drew</creatorcontrib><creatorcontrib>Besman, Marc</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Anti-cancer drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Singer, Jack W</au><au>Shaffer, Scott</au><au>Baker, Brian</au><au>Bernareggi, Alberto</au><au>Stromatt, Scott</au><au>Nienstedt, Drew</au><au>Besman, Marc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane</atitle><jtitle>Anti-cancer drugs</jtitle><addtitle>Anticancer Drugs</addtitle><date>2005-03</date><risdate>2005</risdate><volume>16</volume><issue>3</issue><spage>243</spage><epage>254</epage><pages>243-254</pages><issn>0959-4973</issn><eissn>1473-5741</eissn><abstract>Paclitaxel poliglumex (CT-2103; XYOTAX) is an innovative macromolecular taxane designed to increase the therapeutic index of paclitaxel. This large macromolecule conjugate of paclitaxel and poly-L-glutamic acid accumulates in tumor tissues by taking advantage of the enhanced permeability of tumor vasculature and lack of lymphatic drainage. Paclitaxel poliglumex prolongs exposure to active drug and minimizes systemic exposure. Preclinical studies in animal tumor models demonstrate enhanced safety and efficacy relative to paclitaxel when administered as a single agent or in conjunction with radiation. Clinical pilot studies with paclitaxel poliglumex showed improved outcomes compared to standard taxanes and allowed a more convenient administration schedule. Human pharmacokinetic data are consistent with prolonged tumor exposure to active drug and a limited systemic exposure. Based on these results, three ongoing randomized phase III trials were initiated to test the efficacy of paclitaxel poliglumex in patients with advanced non-small cell lung carcinoma.</abstract><cop>England</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>15711176</pmid><doi>10.1097/00001813-200503000-00003</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-4973 |
| ispartof | Anti-cancer drugs, 2005-03, Vol.16 (3), p.243-254 |
| issn | 0959-4973 1473-5741 |
| language | eng |
| recordid | cdi_pubmed_primary_15711176 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Animals Antineoplastic Agents - therapeutic use Area Under Curve Carcinoma, Non-Small-Cell Lung - drug therapy Drug Synergism Female Half-Life Humans Lung Neoplasms - drug therapy Mice Ovarian Neoplasms - drug therapy Paclitaxel - therapeutic use Polyglutamic Acid - metabolism Polyglutamic Acid - pharmacokinetics Polyglutamic Acid - therapeutic use Randomized Controlled Trials as Topic Taxoids - metabolism Taxoids - pharmacokinetics Taxoids - therapeutic use |
| title | Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T13%3A09%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_wolte&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Paclitaxel%20poliglumex%20(XYOTAX;%20CT-2103):%20an%20intracellularly%20targeted%20taxane&rft.jtitle=Anti-cancer%20drugs&rft.au=Singer,%20Jack%20W&rft.date=2005-03&rft.volume=16&rft.issue=3&rft.spage=243&rft.epage=254&rft.pages=243-254&rft.issn=0959-4973&rft.eissn=1473-5741&rft_id=info:doi/10.1097/00001813-200503000-00003&rft_dat=%3Cpubmed_wolte%3E15711176%3C/pubmed_wolte%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/15711176&rfr_iscdi=true |